BC Extra | Dec 11, 2019
Clinical News

Leo’s IL-13 mAb hits in atopic dermatitis; how it stacks up against Dupixent remains a question mark

Over a year after the primary completion of tralokinumab’s Phase III studies, Leo Pharma has said the anti-IL-13 mAb met the primary endpoint in all three trials to treat moderate-to-severe atopic dermatitis without divulging details....
BC Innovations | Sep 18, 2019
Emerging Company Profile

Divide & Conquer: short-circuiting tumor lines of communication

Divide & Conquer aims to capitalize on new tumor biology that would prevent cancer cells from sharing resistance mechanisms and resensitize the tumor to chemo- and radiotherapy. Medicxi’s David Grainger founded the company in 2018...
BC Extra | Aug 30, 2019
Politics & Policy

FDA urged to expand on integrated review

A new FDA drug review template, part of an integrated review system unveiled in June, is raising concerns that data that would be valuable for drug development and for informing treatment decisions could be left...
BC Extra | Jun 3, 2019
Company News

Management tracks: Zai, Jazz, PTC, BIO and more

Cancer company Zai Lab Ltd. (NASDAQ:ZLAB) hired Valeria Fantin as its first CSO. She was CSO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Cancer and neurology company Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hired Robert Iannone...
BC Extra | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
BC Week In Review | Nov 30, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib to treat rare skin cancer Gorlin syndrome. PellePharm will receive...
BC Extra | Nov 20, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib to treat rare skin cancer Gorlin syndrome. PellePharm will receive...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BC Week In Review | Oct 26, 2018
Company News

Leo, Zymeworks partner on bispecific antibodies

Leo Pharma A/S (Ballerup, Denmark) and Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) partnered to discover and develop bispecific antibodies targeting cytokine signaling pathways to treat dermatology, autoimmune and inflammatory diseases. The partners will use Zymeworks' Azymetric platform,...
BC Week In Review | Aug 31, 2018
Company News

JW grants Leo rights to atopic dermatitis candidate JW1601

JW Pharmaceutical Corp. (KSE:001060) granted Leo Pharma A/S (Ballerup, Denmark) exclusive rights to develop and commercialize JW1601 worldwide, excluding Korea. This year, JW expects to submit an IND in Korea for a Phase I trial...
Items per page:
1 - 10 of 183
BC Extra | Dec 11, 2019
Clinical News

Leo’s IL-13 mAb hits in atopic dermatitis; how it stacks up against Dupixent remains a question mark

Over a year after the primary completion of tralokinumab’s Phase III studies, Leo Pharma has said the anti-IL-13 mAb met the primary endpoint in all three trials to treat moderate-to-severe atopic dermatitis without divulging details....
BC Innovations | Sep 18, 2019
Emerging Company Profile

Divide & Conquer: short-circuiting tumor lines of communication

Divide & Conquer aims to capitalize on new tumor biology that would prevent cancer cells from sharing resistance mechanisms and resensitize the tumor to chemo- and radiotherapy. Medicxi’s David Grainger founded the company in 2018...
BC Extra | Aug 30, 2019
Politics & Policy

FDA urged to expand on integrated review

A new FDA drug review template, part of an integrated review system unveiled in June, is raising concerns that data that would be valuable for drug development and for informing treatment decisions could be left...
BC Extra | Jun 3, 2019
Company News

Management tracks: Zai, Jazz, PTC, BIO and more

Cancer company Zai Lab Ltd. (NASDAQ:ZLAB) hired Valeria Fantin as its first CSO. She was CSO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Cancer and neurology company Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hired Robert Iannone...
BC Extra | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
BC Week In Review | Nov 30, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib to treat rare skin cancer Gorlin syndrome. PellePharm will receive...
BC Extra | Nov 20, 2018
Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib to treat rare skin cancer Gorlin syndrome. PellePharm will receive...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BC Week In Review | Oct 26, 2018
Company News

Leo, Zymeworks partner on bispecific antibodies

Leo Pharma A/S (Ballerup, Denmark) and Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) partnered to discover and develop bispecific antibodies targeting cytokine signaling pathways to treat dermatology, autoimmune and inflammatory diseases. The partners will use Zymeworks' Azymetric platform,...
BC Week In Review | Aug 31, 2018
Company News

JW grants Leo rights to atopic dermatitis candidate JW1601

JW Pharmaceutical Corp. (KSE:001060) granted Leo Pharma A/S (Ballerup, Denmark) exclusive rights to develop and commercialize JW1601 worldwide, excluding Korea. This year, JW expects to submit an IND in Korea for a Phase I trial...
Items per page:
1 - 10 of 183